Background: Systemic lupus erythematosus (SLE) is an autoimmune disease with diverse systemic manifestations, including neuropsychiatric involvement (NPSLE), which can vary in severity and prognosis. Diagnosing NPSLE remains challenging, necessitating reliable diagnostic markers. CXCL13, a B-cell chemokine implicated in SLE, has garnered attention for its potential role in NPSLE.
Purpose: This study aimed to assess serum CXCL-13 levels in NPSLE patients compared to SLE patients without neuropsychiatric symptoms and healthy controls.
Research Design: All study groups were studied CXCL-13 levels from blood samples.
Study Sample: One hundred twenty-five participants were categorized into four groups: SLE patients with active NPSLE (n = 6), SLE patients with inactive NPSLE (n = 26), SLE patients without NPSLE (n = 71), and healthy controls (n = 22).
Data Collection and Analyses: Serum samples were collected at the time of enrollment and CXCL-13 levels were analysed by Enzyme Linked ImmunoSorbent Assay (ELISA) method.
Results: Results indicated significantly elevated CXCL-13 levels in active NPSLE patients compared to other SLE patient groups and healthy controls (p < 0.001 for all). Patients with SLE, including those with inactive NPSLE or no history of NPSLE, had statistically significantly higher serum CXCL-13 levels compared to the control group (p < 0.001). Additionally, serum CXCL-13 levels positively correlated with disease activity assessed by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).
Conclusion: This study underscores the association between serum CXCL-13 levels and neuropsychiatric involvement in SLE, as well as their correlation with disease activity. Moreover, previous research suggesting a link between CXCL-13 levels and clinical activity in SLE further supports its potential as a diagnostic marker for NPSLE. Nevertheless, further investigations are warranted to validate the utility of CXCL-13 as a diagnostic tool for NPSLE and its role in disease management.
UntermanANolteJEBoazM, et al.Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum2011; 41(1): 1–11. DOI: 10.1016/j.semarthrit.2010.08.001.
2.
LiuYTuZZhangX, et al.Pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus: a review. Front Cell Dev Biol2022; 10: 998328. DOI: 10.3389/fcell.2022.998328.
3.
NiJChenCWangS, et al.Novel CSF biomarkers for diagnosis and integrated analysis of neuropsychiatric systemic lupus erythematosus: based on antibody profiling. Arthritis Res Ther2023; 25(1): 165. DOI: 10.1186/s13075-023-03146-z.
4.
HasegawaYArinumaYMuramatsuT, et al.The pathogenic role of lupus-specific autoantibodies and Interleukin-6 on demyelination of the brainstem and spinal cord in systemic lupus erythematosus. Lupus2023; 32(3): 401–410. DOI: 10.1177/09612033231151600.
5.
HafezSSSaadWESShedidNH. B-cell-attracting chemokine-1 (BCA-1/CXCL13) in systemic lupus erythematosus, its correlation to disease activity and renal involvement. Egypt J Immunol2014; 21(2): 23–32.
6.
EzzatMEl-GammasyTShaheenK, et al.Elevated production of serum B-cell-attracting chemokine-1 (BCA-1/CXCL13) is correlated with childhood-onset lupus disease activity, severity, and renal involvement. Lupus2011; 20(8): 845–854. DOI: 10.1177/0961203311398513.
7.
NiederkornAFrühaufJSchwantzerG, et al.CXCL13 is an activity marker for systemic, but not cutaneous lupus erythematosus: a longitudinal cohort study. Arch Dermatol Res2018; 310(6): 485–493. DOI: 10.1007/s00403-018-1836-6.
8.
PanZZhuTLiuY, et al.Role of the CXCL13/CXCR5 Axis in autoimmune diseases. Front Immunol2022; 13: 850998. DOI: 10.3389/fimmu.2022.850998.
9.
IshikawaSSatoTAbeM, et al.Aberrant high expression of B lymphocyte chemokine (BLC/CXCL13) by C11b+CD11c+ dendritic cells in murine lupus and preferential chemotaxis of B1 cells towards BLC. J Exp Med2001; 193(12): 1393–1402. DOI: 10.1084/jem.193.12.1393.
10.
Davalos-MisslitzAMHaubitzMHallerH, et al.B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE). Nephrol Dial Transplant2009; 24(12): 3708–3712. DOI: 10.1093/ndt/gfp343.
11.
LeeHTShiaoYMWuTH, et al.Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis. J Rheumatol2010; 37(1): 45–52. DOI: 10.3899/jrheum.090450.
12.
SchifferLWorthmannKHallerH, et al.CXCL13 as a new biomarker of systemic lupus erythematosus and lupus nephritis - from bench to bedside?Clin Exp Immunol2015; 179(1): 85–89. DOI: 10.1111/cei.12439.
13.
WorthmannKGuelerFvon VietinghoffS, et al.Pathogenetic role of glomerular CXCL13 expression in lupus nephritis. Clin Exp Immunol2014; 178(1): 20–27. DOI: 10.1111/cei.12380.
14.
WuBWangWZhanY, et al.CXCL13, CCL4, and sTNFR as circulating inflammatory cytokine markers in primary and SLE-related autoimmune hemolytic anemia. J Transl Med2015; 13: 112. DOI: 10.1186/s12967-015-0474-4.
15.
SchifferLKielsteinJTHaubitzM, et al.Elevation of serum CXCL13 in SLE as well as in sepsis. Lupus2011; 20(5): 507–511. DOI: 10.1177/0961203310383301.
16.
SchifferLWiehlerFBräsenJH, et al.Chemokine CXCL13 as a new systemic biomarker for B-cell involvement in acute T cell-mediated kidney allograft rejection. Int J Mol Sci2019; 20(10): 2552. DOI: 10.3390/ijms20102552.
17.
ZengYZhangYLinY, et al.The CXCL13 chemokine serves as a potential biomarker to diagnose systemic lupus erythematosus with disease activity. Clin Exp Med2021; 21(4): 611–619. DOI: 10.1007/s10238-021-00707-x.
18.
WongCKWongPTTamLS, et al.Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. J Clin Immunol2010; 30(1): 45–52. DOI: 10.1007/s10875-009-9325-5.
19.
AringerMCostenbaderKDaikhD, et al.2019 European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol2019; 71(9): 1400–1412. DOI: 10.1002/art.40930.
20.
The American college of rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum1999; 42(4): 599–608. DOI: 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F.
21.
BombardierCGladmanDDUrowitzMB, et al.Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum1992; 35(6): 630–640. DOI: 10.1002/art.1780350606.
22.
BortoluzziAScirèCABombardieriS, et al.Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology2015; 54(5): 891–898. DOI: 10.1093/rheumatology/keu384.
23.
GovoniMBortoluzziAPadovanM, et al.The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun2016; 74: 41–72. DOI: 10.1016/j.jaut.2016.06.013.
24.
DeijnsSJBroenJCAKruytND, et al.The immunologic etiology of psychiatric manifestations in systemic lupus erythematosus: a narrative review on the role of the blood brain barrier, antibodies, cytokines and chemokines. Autoimmun Rev2020; 19(8): 102592. DOI: 10.1016/j.autrev.2020.102592.
25.
KarassaFBIoannidisJPTouloumiG, et al.Risk factors for central nervous system involvement in systemic lupus erythematosus. QJM2000; 93(3): 169–174. DOI: 10.1093/qjmed/93.3.169.
26.
CoccoCMancaECordaG, et al.Brain-reactive autoantibodies in neuropsychiatric systemic lupus erythematosus. Front Immunol2023; 14: 1157149. DOI: 10.3389/fimmu.2023.1157149.
27.
George-ChandyATrysbergEErikssonK. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther2008; 10(4): R97. DOI: 10.1186/ar2484.
28.
HopiaLThangarajhMKhademiM, et al.Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus. Scand J Rheumatol2011; 40(5): 363–372. DOI: 10.3109/03009742.2010.550900.
29.
WangJBLiHWangLL, et al.Role of IL-1β, IL-6, IL-8 and IFN-γ in pathogenesis of central nervous system neuropsychiatric systemic lupus erythematous. Int J Clin Exp Med2015; 8(9): 16658–16663.
30.
LuXYZhuCQQianJ, et al.Intrathecal cytokine and chemokine profiling in neuropsychiatric lupus or lupus complicated with central nervous system infection. Lupus2010; 19(6): 689–695. DOI: 10.1177/0961203309357061.
31.
Fragoso-LoyoHRichaud-PatinYOrozco-NarváezA, et al.Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum2007; 56(4): 1242–1250. DOI: 10.1002/art.22451.
32.
TrysbergECarlstenHTarkowskiA. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus2000; 9(7): 498–503. DOI: 10.1177/096120330000900704.
33.
Fragoso-LoyoHAtisha-FregosoYNúñez-AlvarezCA, et al.Utility of interferon-α as a biomarker in central neuropsychiatric involvement in systemic lupus erythematosus. J Rheumatol2012; 39(3): 504–509. DOI: 10.3899/jrheum.110983.
34.
HuangMWStockADPuttermanC. CXCL13 neutralization attenuates neuropsychiatric manifestations in lupus-prone mice. Front Immunol2021; 12: 763065. DOI: 10.3389/fimmu.2021.763065.
35.
CannySPJacksonSW. B cells in systemic lupus erythematosus: from disease mechanisms to targeted therapies. Rheum Dis Clin N Am2021; 47(3): 395–413. DOI: 10.1016/j.rdc.2021.04.006.
36.
SzelinskiFLinoACDörnerT. B cells in systemic lupus erythematosus. Curr Opin Rheumatol2022; 34(2): 125–132. DOI: 10.1097/BOR.0000000000000865.
37.
MaKDuWWangX, et al.Multiple functions of B cells in the pathogenesis of systemic lupus erythematosus. Int J Mol Sci2019; 20(23): 6021. DOI: 10.3390/ijms20236021.
GunnMDNgoVNAnselKM, et al.A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature1998; 391(6669): 799–803. DOI: 10.1038/35876.
40.
VissersJLHartgersFCLindhoutE, et al.BLC (CXCL13) is expressed by different dendritic cell subsets in vitro and in vivo. Eur J Immunol2001; 31(5): 1544–1549. DOI: 10.1002/1521-4141(200105)31:5<1544::AID-IMMU1544>3.0.CO;2-I.
41.
HussainMAdahDTariqM, et al.CXCL13/CXCR5 signaling axis in cancer. Life Sci2019; 227: 175–186. DOI: 10.1016/j.lfs.2019.04.053.
42.
LiYTangLGuoL, et al.CXCL13-mediated recruitment of intrahepatic CXCR5+CD8+ T cells favors viral control in chronic HBV infection. J Hepatol2020; 72(3): 420–430. DOI: 10.1016/j.jhep.2019.09.031.
43.
CagigiAMowafiFPhuong DangLV, et al.Altered expression of the receptor-ligand pair CXCR5/CXCL13 in B cells during chronic HIV-1 infection. Blood2008; 112(12): 4401–4410. DOI: 10.1182/blood-2008-02-140426.
44.
HeNChenWLLongKX, et al.Association of serum CXCL13 with intrarenal ectopic lymphoid tissue formation in lupus nephritis. J Immunol Res2016; 2016: 4832543. DOI: 10.1155/2016/4832543.
45.
RibeiroDSLinsCFGalvãoV, et al.Association of CXCL13 serum level and ultrasonographic findings of joints in patients with systemic lupus erythematosus and Jaccoud's arthropathy. Lupus2018; 27(6): 939–946. DOI: 10.1177/0961203317753557.
46.
TomallaVSchmeisserMJWeinmann-MenkeJ. Mouse models, antibodies, and neuroimaging: current knowledge and future perspectives in neuropsychiatric systemic lupus erythematosus (NPSLE). Front Psychiatr2023; 14: 1078607. DOI: 10.3389/fpsyt.2023.1078607.
47.
PamukONRazaAAHasniS. Neuropsychiatric lupus in late and early onset systemic lupus erythematosus patients: a systematic review and meta-analysis. Rheumatology (Oxford)2023; 63(1): 8–15. DOI: 10.1093/rheumatology/kead297.
48.
HirohataSArinumaYTakayamaM, et al.Association of cerebrospinal fluid anti-ribosomal p protein antibodies with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Arthritis Res Ther2007; 9(3): R44. DOI: 10.1186/ar2184.
49.
KarassaFBAfeltraAAmbrozicA, et al.Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum2006; 54(1): 312–324. DOI: 10.1002/art.21539.
50.
EberTChapmanJShoenfeldY. Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality?Lupus2005; 14(8): 571–575. DOI: 10.1191/0961203305lu2150rr.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
